Lactoferrin
Also called: bovine lactoferrin, Lf, cow's milk-derived lactoferrin
Lactoferrin is a glycoprotein present in human and bovine milk and a normal component of human colostrum. Research has studied oral bovine (cow's milk-derived) lactoferrin and lactoferrin added to infant feeds.
- Category
- Amino acid and protein
- Forms
- Bovine (cow's milk-derived) lactoferrin, oral or added to enteral feeds and formulas
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2020 Cochrane review pooled 12 randomized controlled trials (5,425 preterm infants) of lactoferrin added to enteral feeds; trials combining lactoferrin with probiotics were analyzed separately. [1]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BLungs and airways1 topic
BStomach and gut1 topic
BSeveral areas, whole body or blood1 topic
BPregnancy and infants1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Late-onset sepsis and necrotizing enterocolitis in preterm infants | B | A 2020 Cochrane review (12 RCTs, 5,425 preterm infants) found lactoferrin added to enteral feeds reduced late-onset sepsis (RR 0.82; low certainty) but not NEC stage II–III or all-cause mortality. [1] |
| Respiratory tract infections and inflammation markers | B | A 2022 meta-analysis (25 studies) found fewer respiratory infections in infants and children (OR 0.78) but not in adults (OR 1.00); in adults lactoferrin lowered IL-6 but not C-reactive protein. [2] |
| Helicobacter pylori eradication | B | A 2009 meta-analysis of 5 RCTs (682 infected subjects) found higher eradication rates in groups given bovine lactoferrin (pooled OR 2.22), with no difference in adverse effects; the authors call the evidence limited. [3] |
| Iron deficiency anemia in pregnancy (compared with ferrous sulfate) | B | A 2017 meta-analysis of 4 RCTs (600 pregnant women) found hemoglobin rose more at 4 weeks with daily oral bovine lactoferrin than with ferrous sulfate (mean difference 0.77), with fewer gastrointestinal side effects. [4] |
Main constituents: Lactoferrin, a milk glycoprotein with antimicrobial and immune-modulating properties [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studies in adults showing lower systemic inflammation used 200 mg lactoferrin/day; formulas in infant and child studies provided 35–833 mg/day. [2]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingIn a 2017 meta-analysis of 4 RCTs (600 pregnant women with iron deficiency anemia), daily oral bovine lactoferrin versus ferrous sulfate showed no …
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Investigators reported no adverse effects in the preterm-infant trials included in the 2020 Cochrane review. [1]
- In the H. pylori meta-analysis, adverse effects did not differ significantly between lactoferrin and control groups. [3]
- Compared with ferrous sulfate in pregnant women with iron deficiency anemia, lactoferrin caused significantly fewer gastrointestinal side effects. [4]
Regulatory status
- US: FDA had no questions about GRAS Notice 669 for cows milk-derived lactoferrin in cow's milk-based non-exempt infant formula for term infants at 100 mg/100 g formula solids (closed March 9, 2017). [5]
- US: FDA had no questions about GRAS Notice 130 for bovine milk-derived lactoferrin as an antimicrobial spray on beef carcasses (closed August 21, 2003). [6]
- US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [7]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Lactoferrin, a glycoprotein present in human and bovine milk with antimicrobial and immune-modulating properties Amino acids, amines and peptides (glycoprotein) [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming lactoferrin (cow's milk derived; NDI 751 submitted 2012-03-19). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P1]
- FDA's GRAS Notice Inventory lists 15 notices whose substance names include lactoferrin (searched 2026-10-29); for GRN 669, cows milk-derived lactoferrin in term infant formula at 100 mg/100 g formula solids, FDA had no questions (closed March 9, 2017). [P6]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- In a 2017 meta-analysis of 4 RCTs (600 pregnant women with iron deficiency anemia), daily oral bovine lactoferrin versus ferrous sulfate showed no significant differences in preterm birth, low birthweight, neonatal death or mean birthweight. [P7]
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- Berthon BS, et al. Effect of lactoferrin supplementation on inflammation, immune function, and prevention of respiratory tract infections in humans: a systematic review and meta-analysis. Adv Nutr 2022;13(5):1799-1819 (PMID 35481594), 2022-10-02. pubmed.ncbi.nlm.nih.gov
- U.S. FDA. GRAS Notice Inventory: search results for 'lactoferrin' (retrieved 2026-10-29), 2026-10-29. hfpappexternal.fda.gov
- Abu Hashim H, et al. Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: a meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol 2017;219:45-52 (PMID 29059584), 2017-12. pubmed.ncbi.nlm.nih.gov
Sources
- Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2020;3:CD007137 (PMID 32232984), 2020-03-31. pubmed.ncbi.nlm.nih.gov
- Berthon BS, et al. Effect of lactoferrin supplementation on inflammation, immune function, and prevention of respiratory tract infections in humans: a systematic review and meta-analysis. Adv Nutr 2022;13(5):1799-1819 (PMID 35481594), 2022-10-02. pubmed.ncbi.nlm.nih.gov
- Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009;29(7):720-730 (PMID 19183156), 2009-04-01. pubmed.ncbi.nlm.nih.gov
- Abu Hashim H, et al. Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: a meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol 2017;219:45-52 (PMID 29059584), 2017-12. pubmed.ncbi.nlm.nih.gov
- U.S. FDA. GRAS Notice Inventory: GRN No. 669, Cows milk-derived lactoferrin, 2017-03-09. hfpappexternal.fda.gov
- U.S. FDA. GRAS Notice Inventory: GRN No. 130, Bovine milk-derived lactoferrin, 2003-08-21. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.